Last reviewed 2026-06-02 · How we verify

Aablaquine (BULAQUINE)

Phase 2 active Small molecule

Aablaquine (generic name: BULAQUINE) is a bulaquine drug. It is currently in Phase 2 development.

Aablaquine works by inhibiting the activity of certain enzymes involved in the replication of parasites.

Aablaquine, also known as Bulaquine, is a small molecule drug in the bulaquine class. It is a synthetic compound developed for treating various diseases, but its exact target and approved indications are unknown. The commercial status of Aablaquine is unclear, and it may be patented or have generic manufacturers. Further research is needed to determine its safety profile and pharmacokinetic properties. As a result, Aablaquine is not widely recognized or used in clinical practice.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BULAQUINE
Drug class	bulaquine
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of Aablaquine like a key that locks up the machinery inside parasites, preventing them from making copies of themselves. This helps to stop the spread of the infection and allows the body's immune system to fight off the disease. By targeting these enzymes, Aablaquine can help to treat various parasitic infections.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aablaquine CI brief — competitive landscape report
Aablaquine updates RSS · CI watch RSS

Frequently asked questions about Aablaquine

What is Aablaquine?

Aablaquine (BULAQUINE) is a bulaquine drug.

How does Aablaquine work?

Aablaquine works by inhibiting the activity of certain enzymes involved in the replication of parasites.

What is the generic name of Aablaquine?

BULAQUINE is the generic (nonproprietary) name of Aablaquine.

What drug class is Aablaquine in?

Aablaquine belongs to the bulaquine class. See all bulaquine drugs at /class/bulaquine.

What development phase is Aablaquine in?

Aablaquine is in Phase 2.

Drug class: All bulaquine drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing